Fasting mimicking diet during neo-adjuvant chemotherapy in breast cancer patients: a randomized controlled trial study
2024

Fasting Mimicking Diet During Chemotherapy for Breast Cancer

Sample size: 44 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bahrami Alireza, Haghighi Shirin, Moghani Mona Malekzadeh, Khodakarim Nastaran, Hejazi Ehsan

Primary Institution: Shahid Beheshti University of Medical Sciences, Tehran, Iran

Hypothesis

Does a fasting mimicking diet reduce chemotherapy toxicity and improve metabolic parameters in breast cancer patients?

Conclusion

The fasting mimicking diet was well tolerated during chemotherapy and reduced toxicity while improving some metabolic parameters.

Supporting Evidence

  • The FMD group experienced significantly lower rates of grade III vomiting and neutropenia compared to the control group.
  • Erythrocyte and neutrophil counts were significantly higher in the FMD group after 8 cycles.
  • Median glucose and insulin levels increased in the control group but remained stable in the FMD group.
  • Median levels of IGF-1 and hs-CRP decreased significantly in the FMD group.
  • The FMD group had a higher frequency of complete or partial tumor response compared to controls.

Takeaway

Eating less during chemotherapy can help patients feel better and may help the medicine work better against cancer.

Methodology

Patients were randomized to receive either a fasting mimicking diet or a regular diet for 3 days before and during chemotherapy, repeated every 3 weeks for 8 cycles.

Potential Biases

Possible bias due to the subjective reporting of side effects and the influence of dexamethasone on glucose levels.

Limitations

Small sample size and potential incomplete adherence to the fasting mimicking diet.

Participant Demographics

Participants were newly diagnosed HER2-negative breast cancer patients aged 35 to 68 years, with a mean age of 49.36 years.

Statistical Information

P-Value

p<0.001 for vomiting, p=0.04 for neutropenia, p=0.01 for erythrocytes, p=0.002 for neutrophils, p=0.01 for IGF-1, p=0.02 for hs-CRP.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fnut.2024.1483707

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication